| 產(chǎn)品名稱 |
huFasM3 |
| 商品貨號 |
B164804 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain |
Strain: BALB/c (B cell); BALB/c (myeloma) |
| Applications |
The antibody reacts with the extracellular domain of human Fas and blocks Fas dependent killing of Jurkat cells (a human T cell line). It inhibits the binding of other Fas specific antibodies, and inhibits Fas-L mediated lysis of T cell targets. Cross linked and immobilized huFasM3 stimulates lysis of Fas expressing cells. |
| Storage Conditions |
liquid nitrogen vapor phase |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Spleen cells were fused with P3X63Ag8.653 myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against human Fas antigen |
| Cellular Products |
immunoglobulin; monoclonal antibody; against human Fas antigen |
| Comments |
Animals were immunized with a fusion protein containing the extracellular protion of human Fas and human IgG1 Fc region. Spleen cells were fused with P3X63Ag8.653 myeloma cells. The antibody reacts with the extracellular domain of human Fas and blocks Fas dependent killing of Jurkat cells (a human T cell line). It inhibits the binding of other Fas specific antibodies, and inhibits Fas-L mediated lysis of T cell targets. Cross linked and immobilized huFasM3 stimulates lysis of Fas expressing cells. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing |
Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml. Maintain cultures at a cell concentration between 1 X 10(5) and 1 x 10(6) cells/ml. Do not allow the cell concentration to exceed 1 X 10(6) cells/ml. Medium Renewal: Every 2 to 3 days |
| Cryopreservation |
Freeze medium: Complete growth medium supplemented with 7.5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions |
Temperature: 37.0°C |
| Isotype |
IgG1 , IgG1 |
| Name of Depositor |
Immunex Corporation |
| Deposited As |
mouse (B cell); mouse (myeloma) |
| U.S. Patent Number |
|
| References |
Lynch DH, Alderson MR. Human anti-FAS IGG1 monoclonal antibodies. US Patent 5,620,889 dated Apr 15 1997
Lynch DB, Alderson MR. Fas antagonists and uses thereof. US Patent 5,830,469 dated Nov 3 1998
|
